BCAX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 7.09%, SMA50 1.51%, SMA200 19.51%). The stock’s 14-day RSI is 56.1 (neutral), while the ATR of 1.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.76% below its high and over 115.38% above its low. Average 10-day trading volume of 582.99 thousand shares is in line with the 3-month average of 535.60 thousand, indicating normal recent market interest.

Bicara Therapeutics Inc. Common Stock has 64.80 million shares outstanding. The public float is 35.26 million shares, elevated short interest at 20.75% of float. This equals 9.36 million shares. The short ratio is 14.67 days. Institutional investors hold 106.96% of the float. Insiders own 12.23%. RA CAPITAL MANAGEMENT, L.P. holds 2.20 million shares, Mazumdar Claire has 339.39 thousand shares and Cohlhepp Ryan has 200.64 thousand shares. Over the past six months, insider transactions show net selling. They sold 170.50 thousand shares across 26 transactions.

Bicara Therapeutics Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.74. This means the shares are trading above this model’s fair value.

Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) closed at $23.43 USD, losing -$0.29 (-1.22%) from the previous close of $23.72. The stock is currently within 5% of its 52-week high $7.80 and $24.00. With a market capitalization of about $1.28 billion, Bicara Therapeutics Inc. Common Stock is classified as a small-cap and shows lower-than-market volatility (beta ~-1.23). Key stats such as the average daily volume over the past year has been around 552.04 thousand shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Bicara Therapeutics Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Claire Mazumdar Clemon, the company employs approximately 55 people and listed since September 13, 2024. Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors.

Wall Street analysts project EPS growth of 8.12% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 4 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $42.00 to $8.00. The high target offers 82.77% upside. The low target suggests -65.19% downside. The mean target is $26.57. This offers 15.62% upside. Bicara Therapeutics Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 21.06%. The prior quarter beat by -7.41%. Over the last six quarters, Apple has recorded several small beats. These include 247.83% in November 12, 2024.

Our AI price prediction model suggests that Bicara Therapeutics Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.31%, with price expected at $23.97 by April 28, 2026, within a range of $22.93 to $24.95 3-Month Outlook: Projected fall of -19.32%, reaching $18.54 by July 13, 2026, with a range of $17.41 to $19.50. 1-Year Outlook: Projected gain of 5.4%, with price at $24.22 by April 14, 2027, within a range of $22.65 to $25.77.

Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) shares are flat -0.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Bicara Therapeutics Inc. Common Stock trading at a premium to the broader market with a P/E of -9.22. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $30.00, suggesting 30.55% upside. Our AI forecast model points to short-term strength (4.31% over two weeks), a medium-term fall (-19.32% over three months), and a longer-term gain (5.4% over one year), with expected trading ranges indicating moderate volatility.

Bicara Therapeutics Inc. Common Stock trades at a P/E ratio of -9.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.17 trading at moderately above to book value. The P/FCF stands at -11.8, also above market averages.